Nov 16, 2020
Accenture, Orexo Team to Offer Digital Therapeutics through INTIENT(TM) Platform
Oct 15, 2020
Orexo and Lyfebulb Announce the Winner of the 2020 Innovation Challenge in Substance Use Disorders
Sep 25, 2020
Invitation - Orexo Digital Therapeutics business update October 1
Sep 09, 2020
Orexo and GoGoMeds Partner to Bring Digital Therapies to Populations Battling Addiction and Depression with Limited Support Options
Sep 01, 2020
Orexo and Lyfebulb Announce the Finalists and Jury for the 2020 Innovation Challenge in Substance Use Disorders
Aug 10, 2020
Orexo receives paragraph IV Notice Letter for ZUBSOLV® in the US
Jul 16, 2020
Orexo Interim Report Q2 2020
Jun 30, 2020
Positive Results from Human PK Study Assessing Orexo's Intranasal Nalmefene Formulations for Opioid Overdose Reversal
Jun 17, 2020
Orexo and Lyfebulb Announce Call for Digital Solutions to Treat Substance Use Disorder
May 19, 2020
Report From Orexo AB's Extraordinary General Meeting, 19 May 2020
May 15, 2020
Orexo's Partner Gesynta Pharma Announces Positive Results from Phase 1 Study for OX-MPI
May 11, 2020
Orexo Acquires Exclusive US Rights to Commercialize deprexis®, A World-leading Digital Therapy to Help Patients Manage the Symptoms of Depression
Apr 28, 2020
Orexo Presents the Interim Report for Q1 2020
Apr 16, 2020
Report from Orexo's Annual General Meeting, 16 April 2020
Apr 16, 2020
Notice of Extraordinary General Meeting of Orexo
Apr 16, 2020
James Noble Appointed as Chairman of the Board
Apr 09, 2020
The Board of Directors of Orexo Withdraws Proposal on Incentive Program
Apr 06, 2020
Orexo Ends Share Buy-back Program
Mar 26, 2020
Orexo Publishes the Annual Report for 2019
Mar 25, 2020
Orexo Has Repurchased 14 Percent of Own Corporate Bonds